Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Brain Neoplasms 3Paraganglioma, Extra-Adrenal 2Neoplasms 2Glioma 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Meningeal Carcinomatosis 1Melanoma 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Medullary 1Biliary Tract Neoplasms 1

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioma × lenvatinib × CNS × Clear all
NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Eisai Inc.

Phase 1/2 Completed
64 enrolled 29 charts
CNSSarcoma

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT01137604 2022-09-29

A Study in Subjects With Recurrent Malignant Glioma

Eisai Inc.

Phase 2 Completed
151 enrolled 17 charts
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡